Vaporizing Devices And Methods For Delivering A Compound Using The Same

What is this patent about?

’214 is related to the field of medical vaporization devices and methods for the controlled delivery of therapeutic compounds. Specifically, it addresses the technical challenges of precisely extracting active ingredients from plant materials, such as cannabis, while avoiding the harmful byproducts associated with combustion or accidental pyrolysis.

The underlying idea behind ’214 is a multi-stage thermal extraction process that separates the chemical conversion of precursors from the actual vaporization of the active compound. By utilizing a segmented heating profile, the system first prepares the material at a lower temperature to optimize its chemical state—such as through decarboxylation—before rapidly elevating the heat to a specific vaporization window. This ensures that the resulting vapor contains a high concentration of the desired therapeutic agent with minimal degradation or non-uniform heating.

The claims of ’214 focus on a method for treating disorders by heating a volume of material to a first temperature between 140°C and 160°C for a duration of 5 to 15 seconds, followed by a second heating stage to a higher temperature between 190°C and 200°C. This specific sequence is designed to decarboxylate precursors like THCA or CBDA into active THC or CBD before generating a metered dose of vapor for administration. The independent claims also encompass the broader concept of reducing the concentration of temperature-sensitive components in a first stage to prepare the material for final vaporization.

In practice, the invention is implemented using a capsule-based system where the plant material is sandwiched between two electrically conductive meshes. These meshes act as resistive heating elements, allowing for nearly instantaneous temperature adjustments that are far more precise than traditional convection-based vaporizers. The device incorporates a control unit that can adjust the thermal output in real-time based on detected airflow, ensuring that the concentration of the compound remains consistent regardless of how hard the user inhales.

This approach differs from prior solutions by eliminating the high inter-individual variability and low efficiency common in smoking or standard vaporization. By precisely controlling the thermal transition from precursor conversion to vaporization, the device achieves a significantly higher peak plasma concentration of the active ingredient per milligram of material. Furthermore, the use of phase-change materials or resistance-based identification allows the system to automatically recognize capsule types and apply the ideal heating curve, preventing the material from ever reaching the pyrolysis threshold that creates smoke.